Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Multiple myeloma (MM) is a plasma cell malignancy with a multifaceted immune dysfunction. Indoleamine 2,3-dioxygenase 1 (IDO1) degrades tryptophan into kynurenine (KYN), which inhibits effector T cells and promote regulatory T-cell (Treg) differentiation. It is presently unknown whether MM cells express IDO1 and whether IDO1 activity correlates with immune system impairment. Methods: We investigated IDO1 expression in 25 consecutive patients with symptomatic MM and in 7 patients with either monoclonal gammopathy of unknown significance (MGUS; n=3) or smoldering MM (SMM; n=4). IDO1-driven tryptophan breakdown was correlated with the release of hepatocyte growth factor (HGF) and with the frequency of Treg cells and NY-ESO-1-specific CD8+ T cells. Results: KYN was increased in 75% of patients with symptomatic MM and correlated with the expansion of CD4+CD25+FoxP3+ Treg cells and the contraction of NY-ESO-1-specific CD8+ T cells. In vitro, primary MM cells promoted the differentiation of allogeneic CD4+ T cells into bona fide CD4+CD25 hi FoxP3 hi Treg cells and suppressed IFN-γ/IL-2 secretion, while preserving IL-4 and IL-10 production. Both Treg expansion and inhibition of Th1 differentiation by MM cells were reverted, at least in part, by d,l-1-methyl-tryptophan, a chemical inhibitor of IDO. Notably, HGF levels were higher within the BM microenvironment of patients with IDO+ myeloma disease compared with patients having IDO- MM. Mechanistically, the antagonism of MET receptor for HGF with SU11274, a MET inhibitor, prevented HGF-induced AKT phosphorylation in MM cells and translated into reduced IDO protein levels and functional activity. Conclusions: These data suggest that IDO1 expression may contribute to immune suppression in patients with MM and possibly other HGF-producing cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“A large majority of human tumors, including prostate, pancreatic and colorectal carcinomas, express IDO in a constitutive manner [43].”
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037 · cited 1×
“In this respect, activation of the KYN pathway has been reported in patients with autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis, likely as a result of IDO1 expression by non-hematopoietic cell types, such as fibroblasts, epithelial cells and vascular endothelial…”
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932 · cited 1×
“Furthermore, BM stromal cells (BMSC) in MM secrete immunomodulatory and pro-angiogenic molecules, such as TGF-β, vascular endothelial growth factor, IL-6 and hepatocyte growth factor (HGF) [22,23].”
Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614 · cited 1×
“dendritic cells (DC) [6], by acute myeloid leukemia [7,8] and by a variety of solid tumors, such as colorectal cancer [9], melanoma [10] and serous ovarian cancer [11].”
Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.3.1104.bloodjournal8731104 · Cited by 563
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065464 · Cited by 501 · cited 4×
“None Alive/MGUS 13 MM Onset Micromolecular, κ Normal III Auto-HSCT Alive/CR 14 MM Relapse IgA κ Del(13q) I Prednisone Alive/PD 15 MM Onset NA Normal II None NA 16 MM Partial response IgG λ Normal III PDN Alive/Stable disease 17 MM Relapse IgA λ Normal III PDN Alive/PR 18 SMM Onset IgA κ Normal N.A.”
InfluentialSelf-citationKumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood · doi:10.1182/blood-2011-11-395749 · Cited by 446 · cited 1×
“In recent years, the introduction of autologous hematopoietic stem cell transplantation (HSCT) and the availability of novel drugs such as thalidomide, lenalidomide and bortezomib, have prolonged overall survival [16,17].”
A peripheral circulating compartment of natural naive CD4 Tregs
Valmori, D., Merlo, A., Souleimanian, N. E., Hesdorffer, C. S., & Ayyoub, M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23963 · Cited by 319 · cited 23×
“Interestingly, the provision of tryptophan-depleted and KYN-enriched supernatants from MM BMSC translated into a significant increase of CD4+CD25+FoxP3hi Treg cells (Figure 2C).”
InfluentialGiuliani, N., Colla, S., Sala, R., Moroni, M., Lazzaretti, M., La Monica, S., Bonomini, S., Hojden, M., Sammarelli, G., Barillè, S., et al. (2002) · Blood · doi:10.1182/blood-2002-04-1121 · Cited by 270 · cited 1×
“Other reports have also attributed to MM cell lines, such as U266 and RPMI-8226 cells, and to fresh MM cells the ability to down-regulate IFN-γ release by both un-activated and activated T lymphocytes [55].”
Cited by
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
García-Ortiz, A., Rodríguez-García, Y., Encinas, J., Maroto-Martín, E., Castellano, E., Teixidó, J., & Martínez-López, J. (2021) · Cancers · doi:10.3390/cancers13020217 · Cited by 238
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
Papaccio, F., Della Corte, C. M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., & Morgillo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113595 · Cited by 110
Wang, Y., Hu, G.-F., & Wang, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s136259 · Cited by 21
Metadata
- Authors
- Bonanno, G., Mariotti, A., Procoli, A., Folgiero, V., Natale, D., De Rosa, L., Majolino, I., Novarese, L., Rocci, A., Gambella, M., Ciciarello, M., Scambia, G., Palumbo, A., Locatelli, F., De Cristofaro, R., & Rutella, S.
- Venue
- Journal of Translational Medicine
- Published
- 2012-12
- Volume
- 10
- Issue
- 1
- Pages
- 247-247
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W2161197095
- Cited by
- 67
- References
- 11
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. https://app.cochat.ai/papers/10.1186/1479-5876-10-247
- The paper
- Bonanno, G., Mariotti, A., Procoli, A., Folgiero, V., Natale, D., De Rosa, L., Majolino, I., Novarese, L., Rocci, A., Gambella, M., Ciciarello, M., Scambia, G., Palumbo, A., Locatelli, F., De Cristofaro, R., & Rutella, S. (2012). Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-10-247
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.